Icagen institutional investors call Pfizer's $56M offer inadequate

08/14/2011 | MedCityNews.com

Merlin Nexus and New Leaf Venture Partners, Icagen's institutional investors, reiterated their opposition to Pfizer's $56 million offer for the drugmaker, saying the bid is inadequate. Icagen, which is developing painkillers, should be priced $11 to $19 a share, or $100 million to $165 million, the investors said in a letter to Icagen's board of directors.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Litigation
Center for Science in the Public Interest
Washington, DC
Health Plan CEO - Oregon
Trillium Community Health Plan
Eugene, OR
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Associate General Counsel
Patient-Centered Outcomes Research Institute
Washington, D.C , DC